Abstract Number: 1629 • 2012 ACR/ARHP Annual Meeting
Microarray Analysis of Acute and Intercritical Gout
Background/Purpose: We aimed to identify the immune mechanism underlying gouty inflammation using microarrays analysis and modular gene expression signatures. Methods: Whole blood along with clinical…Abstract Number: 1630 • 2012 ACR/ARHP Annual Meeting
Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals
Background/Purpose: Gout is a common and excruciatingly painful inflammatory arthritis caused by hyperuricemia. In addition to various lifestyle risk factors, a substantial genetic predisposition to…Abstract Number: 1633 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Background/Purpose: Ulodesine (BCX4208) is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on therapy for the chronic management of hyperuricemia in…Abstract Number: 1035 • 2012 ACR/ARHP Annual Meeting
Characterisation of New Bone Formation in Gout: A Quantitative Site-by-Site Analysis Using Plain Radiography and Computed Tomography
Background/Purpose: Radiographic descriptions of gout have noted the tendency to hypertrophic bone changes. The aim of this study was to characterise the features of…Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…Abstract Number: 741 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Recurrent Gout Attacks During Hospitalization
Background/Purpose: While anecdotal evidence suggests that risk of recurrent gout attack increases during hospitalization and gout is one of the most common reasons for in-patient…Abstract Number: 743 • 2012 ACR/ARHP Annual Meeting
Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Background/Purpose: There is a growing prevalence of gout in the US and worldwide. Gout is a recognized risk factor for cardiovascular disease (CVD). It is…Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…Abstract Number: 169 • 2012 ACR/ARHP Annual Meeting
Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG which was approved in the US in 2010 for treating hyperuricemia in patients with…Abstract Number: 147 • 2012 ACR/ARHP Annual Meeting
Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Background/Purpose: In replicate, 6-month, randomized, placebo-controlled Phase 3 clinical trials a subgroup of patients with treatment-refractory chronic gout (RCG) who received pegloticase infusions (8 mg)…Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »